ClinicalTrials.gg
CompletedNCT02057692ITCHUpdated Mar 26, 2019Results posted

Evaluation of LUM001 in the Reduction of Pruritus in Alagille Syndrome

A Phase 2 interventional study of LUM001 and Placebo in Alagille Syndrome, sponsored by Mirum Pharmaceuticals, Inc.. Completed at 13 sites in 2 countries. Open to participants aged 12 Months to 18 Years. Per ClinicalTrials.gov, last updated 2019-03-26.

Sponsored by Mirum Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
37
Allocation
Randomized
Ages
12 Months to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Alagille Syndrome by Mirum Pharmaceuticals, Inc. — 2 open to participants now, 2 under way, none of them phase 3. Alagille Syndrome · Mirum Pharmaceuticals, Inc..

Started
2014
with 2 others
Phase 2
6 of 10
none open now
Registered
3rd of 10
by date

Among the 10 studies in Alagille Syndrome by Mirum Pharmaceuticals, Inc., this one is one of 3 that started in 2014, is one of 6 in phase 2, and was the 3rd registered.

Alagille Syndrome

31 studies on the registry are indexed under Alagille Syndrome; 11 are open to participants now.

Browse Alagille Syndrome studies →

Open to participants now

2 of the 10 studies in Alagille Syndrome by Mirum Pharmaceuticals, Inc. are open now, in 9 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 10 Alagille Syndrome studies recruiting now, 7 (70%) set no upper age limit and 3 (30%) stop at 75 or younger; 9 take children under 18; none take healthy volunteers.

This study: 12 Months to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Alagille Syndrome by Mirum Pharmaceuticals, Inc., or all of them as a file.
02

Study summary

The study is a randomized, double-blind, placebo-controlled study in children with Alagille Syndrome (ALGS). The study will investigate the effects of LUM001, compared to placebo, on pruritus, serum bile acids, liver enzymes, and other biochemical markers in patients with ALGS.

03

Conditions studied

  • Alagille Syndrome

Browse trials for

04

Who can participate

Ages eligible
12 Months to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosis of Alagille Syndrome
  2. Evidence of cholestasis
  3. Moderate to severe pruritus
  4. Ability to understand and willingness to sign /assent prior to initiation of any study procedures

Exclusion criteria

Exclusion Criteria:

  1. Surgical disruption of the enterohepatic circulation
  2. Liver transplant
  3. History or presence of other concomitant liver disease
  4. Females who are pregnant or lactating
  5. Known infection
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
37 participants (actual)

Study arms

  • Experimental
    LUM001

    LUM001 for oral administration

    Drug: LUM001

  • Placebo comparator
    Placebo

    Placebo administered orally once each day

    Drug: Placebo

Interventions

  • DrugLUM001

    LUM001 administered orally

  • DrugPlacebo

    Placebo administered orally

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Endpoint (Week 13/Early Termination) in Pruritus

    Pruritus was assessed using Itch report outcome measure (ItchRO\[Obs\]), administered as an electronic diary (eDiary) which was completed by the participants twice daily (morning and evening). ItchRO(Obs) score ranged from 0 to 4, with the higher score indicating increasing itch severity. The highest score between the morning and evening ItchRO(Obs) reports represented the daily score: a measure of the worst itching over the previous 24-hour period.

    Time frame: Baseline, Week 13/Early Termination

Secondary outcomes

  1. Change From Baseline to Endpoint (Week 13/Early Termination) in Fasting Serum Bile Acid (sBA) Level

    Fasting sBA level was measured by using a liquid chromatography mass spectrometry method.

    Time frame: Baseline, Week 13/Early Termination

  2. Change From Baseline to Endpoint (Week 13/Early Termination) in Liver Enzyme Levels

    Liver enzyme levels of alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase and gamma glutamyl transferase were reported here.

    Time frame: Baseline, Week 13/Early Termination

  3. Change From Baseline to Endpoint (Week 13/Early Termination) in Total and Direct Bilirubin Concentrations

    Liver enzyme levels of total bilirubin and direct bilirubin were reported here.

    Time frame: Baseline, Week 13/Early Termination

Other outcomes

  1. Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)

    An AE was any unfavorable and unintended sign (including a clinically significant abnormal laboratory finding, for example), symptom, or disease temporally associated with the study or use of investigational drug product, whether or not the AE was considered related to the investigational drug product. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged in-patient hospitalization; life -threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.TEAEs were defined as AEs/SAEs that started or worsened after the study drug treatment.

    Time frame: From the start of study drug administration up to Week 17

07

Results

Posted Jan 23, 2018

Participant flow

Study was conducted at 13 study centers in the United States and Canada, between 24 November 2014 (first participant first visit) and 16 November 2016 (last participant last visit).

Participant flow — Overall Study
MilestoneMaralixibat 70 mcg/kg/DayMaralixibat 140 mcg/kg/DayMaralixibat 280 mcg/kg/DayPlacebo
Started811612
Completed711611
Not completed1001
Withdrew: Adverse event1000
Withdrew: Lost to follow-up0001

Outcome measures

PrimaryChange From Baseline to Endpoint (Week 13/Early Termination) in Pruritus

Pruritus was assessed using Itch report outcome measure (ItchRO\[Obs\]), administered as an electronic diary (eDiary) which was completed by the participants twice daily (morning and evening). ItchRO(Obs) score ranged from 0 to 4, with the higher score indicating increasing itch severity. The highest score between the morning and evening ItchRO(Obs) reports represented the daily score: a measure of the worst itching over the previous 24-hour period.

Time frame:
Baseline, Week 13/Early Termination
Reported as:
Least squares mean · Score on a scale
Change From Baseline to Endpoint (Week 13/Early Termination) in Pruritus
Score on a scaleMaralixibat 70 mcg/kg/DayMaralixibat 140 mcg/kg/DayMaralixibat 280 mcg/kg/DayPlacebo
Change From Baseline to Endpoint (Week 13/Early Termination) in Pruritus-1.470 ± 0.3034-1.486 ± 0.2597-0.620 ± 0.3575-0.580 ± 0.2453
Statistical analysis
  • Maralixibat 70 mcg/kg/Day vs Placebo · ANCOVA · p = 0.0321 · Ls mean difference: -0.889 · 95% CI -1.698 to 0.081
  • Maralixibat 140 mcg/kg/Day vs Placebo · ANCOVA · p = 0.0145 · Ls mean difference: -0.906 · 95% CI -1.620 to -0.192
  • Maralixibat 280 mcg/kg/Day vs Placebo · ANCOVA · p = 0.9298 · Ls mean difference: -0.039 · 95% CI -0.942 to 0.863
SecondaryChange From Baseline to Endpoint (Week 13/Early Termination) in Fasting Serum Bile Acid (sBA) Level

Fasting sBA level was measured by using a liquid chromatography mass spectrometry method.

Time frame:
Baseline, Week 13/Early Termination
Reported as:
Least squares mean · Micro moles per liter (mcmol/L)
Change From Baseline to Endpoint (Week 13/Early Termination) in Fasting Serum Bile Acid (sBA) Level
Micro moles per liter (mcmol/L)Maralixibat 70 mcg/kg/DayMaralixibat 140 mcg/kg/DayMaralixibat 280 mcg/kg/DayPlacebo
Change From Baseline to Endpoint (Week 13/Early Termination) in Fasting Serum Bile Acid (sBA) Level-117.401 ± 46.2353-40.358 ± 34.8650-27.437 ± 46.2823-10.442 ± 32.6776
SecondaryChange From Baseline to Endpoint (Week 13/Early Termination) in Liver Enzyme Levels

Liver enzyme levels of alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase and gamma glutamyl transferase were reported here.

Time frame:
Baseline, Week 13/Early Termination
Reported as:
Least squares mean · Unit per liter (U/L)
Change From Baseline to Endpoint (Week 13/Early Termination) in Liver Enzyme Levels
Unit per liter (U/L)Maralixibat 70 mcg/kg/DayMaralixibat 140 mcg/kg/DayMaralixibat 280 mcg/kg/DayPlacebo
Alanine Aminotransferase14.616 ± 17.944213.236 ± 14.942429.539 ± 19.6083-11.928 ± 13.9736
Alkaline Phosphatase46.276 ± 38.9056-9.570 ± 30.8065-3.280 ± 42.158232.502 ± 29.9885
Aspartate Aminotransferase20.241 ± 16.846711.851 ± 13.936716.539 ± 18.3472-3.691 ± 13.0114
Gamma Glutamyl Transferase-48.124 ± 46.286748.053 ± 36.1507-10.937 ± 48.8614-37.757 ± 34.7766
SecondaryChange From Baseline to Endpoint (Week 13/Early Termination) in Total and Direct Bilirubin Concentrations

Liver enzyme levels of total bilirubin and direct bilirubin were reported here.

Time frame:
Baseline, Week 13/Early Termination
Reported as:
Least squares mean · Milligrams per deciliter (mg/dL)
Change From Baseline to Endpoint (Week 13/Early Termination) in Total and Direct Bilirubin Concentrations
Milligrams per deciliter (mg/dL)Maralixibat 70 mcg/kg/DayMaralixibat 140 mcg/kg/DayMaralixibat 280 mcg/kg/DayPlacebo
Total Bilirubin-0.291 ± 0.3777-0.353 ± 0.3014-0.804 ± 0.40210.104 ± 0.2847
Direct Bilirubin-0.333 ± 0.2086-0.305 ± 0.1672-0.508 ± 0.22430.011 ± 0.1591
Other pre-specifiedNumber of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)

An AE was any unfavorable and unintended sign (including a clinically significant abnormal laboratory finding, for example), symptom, or disease temporally associated with the study or use of investigational drug product, whether or not the AE was considered related to the investigational drug product. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged in-patient hospitalization; life -threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.TEAEs were defined as AEs/SAEs that started or worsened after the study drug treatment.

Time frame:
From the start of study drug administration up to Week 17
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)
ParticipantsMaralixibat 14 mcg/kg/DayMaralixibat 70 mcg/kg/DayMaralixibat 140 mcg/kg/DayMaralixibat 280 mcg/kg/DayPlacebo
TEAE179512
Serious TEAE01000

Adverse events

Collected over From the start of study drug administration up to Week 17. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Maralixibat 14 mcg/kg/Day0/1 (0%)0/1 (0%)1/1 (100%)
Maralixibat 70 mcg/kg/Day0/7 (0%)1/7 (14.3%)7/7 (100%)
Maralixibat 140 mcg/kg/Day0/11 (0%)0/11 (0%)9/11 (81.8%)
Maralixibat 280 mcg/kg/Day0/6 (0%)0/6 (0%)5/6 (83.3%)
Placebo0/12 (0%)0/12 (0%)12/12 (100%)
Most frequent serious events
Most frequent serious events
EventMaralixibat 14 mcg/kg/DayMaralixibat 70 mcg/kg/DayMaralixibat 140 mcg/kg/DayMaralixibat 280 mcg/kg/DayPlacebo
VomitingGastrointestinal disorders0/11/70/110/60/12
Most frequent other events
Showing 10 of 63
Most frequent other events
EventMaralixibat 14 mcg/kg/DayMaralixibat 70 mcg/kg/DayMaralixibat 140 mcg/kg/DayMaralixibat 280 mcg/kg/DayPlacebo
Pain in extremityMusculoskeletal and connective tissue disorders1/10/70/110/62/12
Alanine aminotransferase increasedInvestigations1/11/70/110/60/12
Aspartate aminotransferase increasedInvestigations1/10/70/110/60/12
Rash maculo-papularSkin and subcutaneous tissue disorders1/10/70/110/60/12
DiarrhoeaGastrointestinal disorders0/10/76/112/66/12
PyrexiaGeneral disorders0/12/72/112/63/12
NasopharyngitisInfections and infestations0/11/70/112/60/12
CoughRespiratory, thoracic and mediastinal disorders0/12/72/112/60/12
Abdominal painGastrointestinal disorders0/12/71/111/62/12
HeadacheNervous system disorders0/12/70/111/60/12

Baseline characteristics

The Safety Population included all participants who were randomly assigned to study treatment and received at least one dose of the study drug.

Age, Continuous
Age, Continuous(Years)Maralixibat 70 mcg/kg/DayMaralixibat 140 mcg/kg/DayMaralixibat 280 mcg/kg/DayPlaceboTotal
Mean7.4 ± 4.758.6 ± 4.325.5 ± 4.765.5 ± 4.196.8 ± 4.48
Sex: Female, Male
Sex: Female, Male(Participants)Maralixibat 70 mcg/kg/DayMaralixibat 140 mcg/kg/DayMaralixibat 280 mcg/kg/DayPlaceboTotal
Female244616
Male672621
08

Study locations

13 sites
  • Children's Hospital Los Angeles
    Los Angeles, California 90027, United States
  • University of California at San Francisco
    San Francisco, California 94143, United States
  • Children's Hospital Colorado
    Aurora, Colorado 80045, United States
  • Children's Healthcare of Atlanta
    Atlanta, Georgia 30322, United States
  • Ann & Robert H. Lurie Children's Hospital of Chicago
    Chicago, Illinois 60611, United States
  • Riley Hospital for Children
    Indianapolis, Indiana 46202, United States
  • Cincinnati Children's Hospital Medical Center
    Cincinnati, Ohio 45229, United States
  • The Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania 19104, United States
  • Children's Hospital of Pittsburgh of UPMC
    Pittsburgh, Pennsylvania 15224, United States
  • Baylor College of Medicine/Texas Children's Hospital
    Houston, Texas 77030, United States
  • University of Utah
    Salt Lake City, Utah 84113, United States
  • Seattle Children's Hospital
    Seattle, Washington 98105, United States
  • The Hospital for Sick Children
    Toronto, Ontario M5G 1X8, Canada
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2014 to primary completion in Nov 2016, 23 months.

Results were first posted in Jan 2018, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 5, 2014
First posted
Feb 7, 2014
StartActual
Nov 24, 2014
Primary completionActual
Nov 16, 2016
CompletionActual
Nov 16, 2016
Results first posted
Jan 23, 2018
Last update
Mar 26, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 26, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02057692
Collaborators
Childhood Liver Disease Research and Education Network
Responsible party
Sponsor
First posted
Feb 7, 2014
Start date
Nov 24, 2014
Primary completion
Nov 16, 2016
Completion
Nov 16, 2016
Results posted
Jan 23, 2018
Last update
Mar 26, 2019

Study contacts

Study Director
study director · Mirum

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Maralixibat

Start the discussion